Loss of TAK1 increases cell traction force in a ROS-dependent manner to drive epithelial-mesenchymal transition of cancer cells.

Lam, C R I

Loss of TAK1 increases cell traction force in a ROS-dependent manner to drive epithelial-mesenchymal transition of cancer cells. [electronic resource] - Cell death & disease Oct 2013 - e848 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

2041-4889

10.1038/cddis.2013.339 doi


Animals
Biomechanical Phenomena--drug effects
Cell Line, Tumor
Cell Membrane--drug effects
Epithelial-Mesenchymal Transition--drug effects
HEK293 Cells
Humans
Integrin beta1--metabolism
Integrin beta3--metabolism
MAP Kinase Kinase Kinases--deficiency
Mice
Models, Biological
Neoplasm Invasiveness
Neoplasms, Squamous Cell--enzymology
Oxidation-Reduction--drug effects
Reactive Oxygen Species--metabolism
Signal Transduction--drug effects
Skin Neoplasms--enzymology
Smad Proteins--metabolism
Transforming Growth Factor beta1--pharmacology
rac1 GTP-Binding Protein--metabolism
rho GTP-Binding Proteins--metabolism